Literature DB >> 29595702

Coinfection with 2 Clostridium difficile ribotypes in China: A case report.

Liqian Wang1, Yun Luo, Chen Huang, Shenghai Wu, Julian Ye, Xiaojun Song, Dazhi Jin, Xianjun Wang.   

Abstract

RATIONALE: Clostridium difficile infections (CDIs) have been reported in China, but detailed clinical symptoms of coinfection by 2 C difficile ribotypes have not been documented. PATIENTS CONCERNS: An 83-year-old male with a 10-day history of diarrhea and urinary tract infection was admitted to the hospital. The patient had received ofloxacin for several days, but his clinical response was poor. Laboratory workup revealed high white blood cell (WBC), serum creatinine (Scr), and C-reactive protein (CRP) levels. Based on these abnormal lab results, rapid detection of glutamate dehydrogenase and toxin A and B was performed. DIAGNOSIS: Severe CDI.
INTERVENTIONS: Oral vancomycin was administered for 8 days. OUTCOMES: Diarrhea symptoms improved and C difficile culture was negative after oral vancomycin administration for 8 days. Clostridium difficile was isolated from 3 consecutive stool samples at 2-day intervals because the patient was admitted to the hospital. Polymerase chain reaction ribotyping revealed ribotype (RT) 017 in the first 2 samples and RT 001 in the third sample. RT 017 caused significantly higher increases in the levels of WBC, Scr, and CRP than RT 001. LESSONS: It is necessary to improve clinicians' awareness of CDI and reduce the severity of CDI caused by RT 017 in China.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29595702      PMCID: PMC5895390          DOI: 10.1097/MD.0000000000009946

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


Introduction

Clostridium difficile is a gram-positive, spore-forming anaerobe that causes symptoms ranging from mild diarrhea to toxic megacolon, colonic perforation, and death.[ The hypervirulent ribotype (RT) 027 has emerged in Europe, North America, and Asia, and produces more TcdA and TcdB toxins than other ribotypes.[ Since 2003, Clostridium difficile infection (CDI) prevalence, severity, and fatality rates have increased dramatically.[ Although most toxigenic strains produce both TcdA and TcdB (A+B+) toxins, strains producing only TcdB (A−B+) have been reported. Some A−B+ strains have been associated with severe cases.[ The epidemiology of CDI has changed dramatically in recent years. Several pathogenic A−B+ strains have emerged in Asia and Latin America.[ Inconsistent with its clinical presentation in North America and Europe, several RT 027 cases in China were not associated with severe symptoms.[ However, severe CDI cases caused by RT 017 have been documented.[ In this study, we have documented, for the first time, a single patient successively infected by 2 different ribotypes in China, and demonstrate that RT 017 caused more severe symptoms than RT 001.

Case report

An 83-year-old male patient with hypertension was admitted to the hospital owing to a 10-day history of diarrhea and urinary tract infection. He received ofloxacin for several days prior to arrival to the hospital. Laboratory workup revealed a white blood cell (WBC) count of 16.2 × 109/L, serum creatinine (Scr) content of 52.7 g/L, and a C-reactive protein (CRP) level of 87 mg/L (Table 1). Based on these abnormal lab results, CDI was suspected. Rapid detection of glutamate dehydrogenase (GDH) and toxin A and B (C. diff Quik Chek Complete, Techlab, Blacksburg, VA) was performed using the patient's stool, which was positive for both GDH and the toxins. According to Society for Healthcare Epidemiology of America/Infectious Diseases Society of America guidelines,[ the case was categorized as severe CDI. Therefore, antimicrobial therapy was switched to oral vancomycin at a dose of 125 mg every 6 h. The course of the patient's disease is shown in Fig. 1. The study was approved by the Ethics Committee, and the informed consent was signed by the patient.
Table 1

Information on the 3 isolates found in the patient.

Figure 1

Course of Clostridium difficile infection in the patient.

Information on the 3 isolates found in the patient. Course of Clostridium difficile infection in the patient. Because the patient had severe diarrhea, we collected stool samples on the 1st, 3rd, and 5th days after hospitalization. All of the diarrhea samples tested positive for C difficile by matrix-assisted laser desorption ionization (Bruke, Karlsruhe, Germany), performed according to the manufacturer's instructions, with a cut-off score > 2.0. Bacterial genomic DNA was extracted using a QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. The housekeeping gene, toxin genes tcdA and tcdB, and binary toxin genes cdtA and cdtB were detected by previously described assays.[ Ribotyping was performed by polymerase chain reaction followed by capillary gel electrophoresis, as described previously,[ and as indicated in Table 1. The patient tested positive for RT 017 (day 1), RT 017 (day 3), and RT 001 (day 5). Clostridium difficile isolates were tested for susceptibility to metronidazole, vancomycin, clindamycin, and erythromycin, using E-test strips (AB Biodisk, Durham, NC) as previously reported.[ The antibiotic susceptibility of the 3 C difficile isolates is presented in Table 1. All isolates were resistant to clindamycin and erythromycin, but sensitive to vancomycin and metronidazole.

Discussion

CDI caused by BI/NAP1/RT 027 strains with both TcdA and TcdB (A+B+) toxins is estimated to cause an economic burden of $3.2 billion per year in the United States.[ Although the RT 027 strain was recently reported in China,[ RT 017 with only TcdB (A−B+) was one of the dominant ribotypes in 2 surveys of Chinese hospitals in Beijing[ and Hangzhou.[ The RT 017 strain is the main cause of moderate-to-severe CDI in hospitals in eastern China, as reported in our previous study.[ This case, with a single patient successively infected with 2 ribotypes, suggests that RT 017 causes more severe clinical symptoms than RT 001, as indicated by the number of stools per day, as well as increased WBC, Scr, and CRP levels (Table 1), which are commonly reported symptoms of CDI.[ Unique to this case, the patient was infected with 2 different ribotypes of C difficile. To rule out the presence of mixed ribotypes in stool samples, 100 suspected colonies were ribotyped in each of the 3 diarrhea samples, and only 1 ribotype was identified in each stool (Table 1). Therefore, we speculate that RT 001 might have come from the environment. However, because environmental sampling was delayed for a week and the ward had been repeatedly disinfected, we were not able to culture RT 001 from the hospital environment. Future environment sampling will be conducted in our hospital to aid in CDI epidemiology. It is noteworthy that a patient with severe diarrhea and high-risk factors for CDI was not diagnosed until 10 days after the presentation of symptoms. CDI has not attracted sufficient attention in China, and a lack of clinical suspicion is the underlying reason for this issue. Thus, it is necessary to improve clinicians’ awareness of CDI and strengthen the cooperation between clinicians and clinical laboratories to detect and treat CDI in a timely manner. In summary, we report a continuous CDI with 2 different ribotypes, of which RT 017 caused more severe symptoms. This case provides the basis for a clinical follow-up study of CDI in China, and confirms that RT 017 is associated with severe clinical symptoms.

Author contributions

Conceptualization: D. Jin, L. Wang, S. Wu, X. Wang, X. Song, Y. Luo. Data curation: C. Huang, D. Jin, J. Ye, L. Wang, S. Wu, X. Wang, X. Song, Y. Luo. Formal analysis: C. Huang, D. Jin, L. Wang, X. Wang, Y. Luo. Funding acquisition: D. Jin, X. Wang. Investigation: L. Wang, X. Wang. Methodology: C. Huang, D. Jin, L. Wang, X. Song. Project administration: D. Jin, L. Wang, Y. Luo. Resources: J. Ye, L. Wang, S. Wu, X. Wang. Software: C. Huang, S. Wu, X. Song, Y. Luo. Supervision: D. Jin, X. Wang. Validation: D. Jin, J. Ye, X. Wang. Visualization: D. Jin, X. Wang. Writing – original draft: L. Wang, X. Wang. Writing – review & editing: D. Jin, L. Wang, X. Wang.
  14 in total

1.  Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe.

Authors:  Michel Warny; Jacques Pepin; Aiqi Fang; George Killgore; Angela Thompson; Jon Brazier; Eric Frost; L Clifford McDonald
Journal:  Lancet       Date:  2005 Sep 24-30       Impact factor: 79.321

2.  Burden of Clostridium difficile infection in the United States.

Authors:  Fernanda C Lessa; Lisa G Winston; L Clifford McDonald
Journal:  N Engl J Med       Date:  2015-06-11       Impact factor: 91.245

3.  The first case of severe Clostridium difficile ribotype 027 infection in Taiwan.

Authors:  Yuan-Pin Hung; Cong-Tat Cia; Bo-Yang Tsai; Po-Chuan Chen; Hsiao-Ju Lin; Hsiao-Chieh Liu; Jen-Chieh Lee; Yi-Hui Wu; Pei-Jane Tsai; Wen-Chien Ko
Journal:  J Infect       Date:  2014-08-21       Impact factor: 6.072

4.  Molecular Epidemiology of Clostridium difficile Infection in Hospitalized Patients in Eastern China.

Authors:  Dazhi Jin; Yun Luo; Chen Huang; Jian Cai; Julian Ye; Yi Zheng; Liqian Wang; Peng Zhao; Anbing Liu; Weijia Fang; Xianjun Wang; Shichang Xia; Jianmin Jiang; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2016-12-14       Impact factor: 5.948

5.  A new type of toxin A-negative, toxin B-positive Clostridium difficile strain lacking a complete tcdA gene.

Authors:  Sandra Janezic; Mercedes Marín; Adoración Martín; Maja Rupnik
Journal:  J Clin Microbiol       Date:  2014-11-26       Impact factor: 5.948

6.  Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

Authors:  Stuart H Cohen; Dale N Gerding; Stuart Johnson; Ciaran P Kelly; Vivian G Loo; L Clifford McDonald; Jacques Pepin; Mark H Wilcox
Journal:  Infect Control Hosp Epidemiol       Date:  2010-05       Impact factor: 3.254

Review 7.  Clostridium difficile infection: epidemiology, diagnosis and understanding transmission.

Authors:  Jessica S H Martin; Tanya M Monaghan; Mark H Wilcox
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-03-09       Impact factor: 46.802

8.  Application of multiple-locus variable-number tandem-repeat analysis to determine clonal spread of toxin A-negative Clostridium difficile in a general hospital in Buenos Aires, Argentina.

Authors:  A Goorhuis; M C Legaria; R J van den Berg; C Harmanus; C H W Klaassen; J S Brazier; G Lumelsky; E J Kuijper
Journal:  Clin Microbiol Infect       Date:  2009-05-11       Impact factor: 8.067

9.  Multilocus sequence typing (MLST) analysis of 104 Clostridium difficile strains isolated from China.

Authors:  Q Yan; J Zhang; C Chen; H Zhou; P Du; Z Cui; R Cen; L Liu; W Li; B Cao; J Lu; Y Cheng
Journal:  Epidemiol Infect       Date:  2012-04-04       Impact factor: 4.434

10.  The First Two Clostridium difficile Ribotype 027/ST1 Isolates Identified in Beijing, China-an Emerging Problem or a Neglected Threat?

Authors:  Jing-Wei Cheng; Meng Xiao; Timothy Kudinha; Zhi-Peng Xu; Xin Hou; Lin-Ying Sun; Li Zhang; Xin Fan; Fanrong Kong; Ying-Chun Xu
Journal:  Sci Rep       Date:  2016-01-07       Impact factor: 4.379

View more
  1 in total

1.  Genomic evolution and virulence association of Clostridioides difficile sequence type 37 (ribotype 017) in China.

Authors:  Xingxing Xu; Yuo Luo; Huan Chen; Xiaojun Song; Qiao Bian; Xianjun Wang; Qian Liang; Jianhong Zhao; Chunhui Li; Guangzhong Song; Jun Yang; Lingli Sun; Jianmin Jiang; Huanying Wang; Bo Zhu; Guangyong Ye; Liang Chen; Yi-Wei Tang; Dazhi Jin
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.